

1 **Best practices for multi-ancestry, meta-analytic transcriptome-wide association studies: lessons**
2 **from the Global Biobank Meta-analysis Initiative**

3

4 Arjun Bhattacharya*^{1,2}, Jibril B. Hirbo*^{3,4}, Dan Zhou^{3,4}, Wei Zhou^{5,6,7}, Jie Zheng⁸, Masahiro Kanai^{5,6,7,9,10},
5 the Global Biobank Meta-analysis Initiative, Mark J. Daly^{5,6,7,11}, Bogdan Pasaniuc^{1,8,9†}, Eric R.
6 Gamazon^{3,4,14†}, Nancy J. Cox^{3,4†}

7

- 8 1. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
9 California, Los Angeles, CA, United States
- 10 2. Institute of Quantitative and Computational Biosciences, David Geffen School of Medicine, University
11 of California, Los Angeles, CA, United States
- 12 3. Department of Medicine, Division of Genetic Medicine, Vanderbilt University School of Medicine,
13 Nashville, TN, United States
- 14 4. Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, United States
- 15 5. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA
- 16 6. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA
- 17 7. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA
- 18 8. MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield
19 House, Oakfield Grove, Bristol, BS8 2BN, UK
- 20 9. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- 21 10. Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita 565-0871,
22 Japan
- 23 11. Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland
- 24 12. Department of Human Genetics, David Geffen School of Medicine, University of California, Los
25 Angeles, CA, United States
- 26 13. Department of Computational Medicine, David Geffen School of Medicine, University of California,
27 Los Angeles, CA, United States
- 28 14. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK

29 *Corresponding authors: Arjun Bhattacharya (abtbhatt@ucla.edu), Jibril Hirbo (jibril.hirbo@vumc.org)

30 †These authors contributed equally to this manuscript.

31 **SUMMARY**

32 The Global Biobank Meta-analysis Initiative (GBMI), through its genetic and demographic diversity,
33 provides a valuable opportunity to study population-wide and ancestry-specific genetic associations.
34 However, with multiple ascertainment strategies and multi-ethnic study populations across biobanks, the
35 GBMI provides a distinct set of challenges in implementing statistical genetics methods. Transcriptome-
36 wide association studies (TWAS) are a popular tool to boost detection power for and provide biological
37 context to genetic associations by integrating single nucleotide polymorphism to trait (SNP-trait)
38 associations from genome-wide association studies (GWAS) with SNP-based predictive models of gene
39 expression. TWAS presents unique challenges beyond GWAS, especially in a multi-biobank and meta-
40 analytic setting like the GBMI. In this work, we present the GBMI TWAS pipeline, outlining practical
41 considerations for ancestry and tissue specificity and meta-analytic strategies, as well as open challenges
42 at every step of the framework. Our work provides a strong foundation for adding tissue-specific gene
43 expression context to biobank-linked genetic association studies, allowing for ancestry-aware discovery to
44 accelerate genomic medicine.

45

46 **KEYWORDS**

47 transcriptome-wide association study; meta-analysis; multi-ancestry genetic analysis; Global Biobank
48 Meta-analysis Initiative

49

50 **INTRODUCTION**

51 Large population-based or clinical-case based biobanks are a key component of precision medicine
52 efforts and provide opportunities for genetic and genomic research (Abul-Husn and Kenny, 2019).
53 Biobanks offer context to deploy genome-wide associations (GWAS) at scale. Multi-biobank
54 collaborations facilitate well-powered, multi-ethnic genetic research (Swede et al., 2007). In addition, such
55 collaborations can accelerate the elucidation of the biological mechanisms that underlie diseases by in-
56 silico longitudinal genetic studies and examination of pleiotropy.

57

58 A key challenge in GWAS is interpreting significant trait-associated loci and these loci to genes or
59 epigenomic features (Gallagher and Chen-Plotkin, 2018; Wijmenga and Zernakova, 2018). Viable
60 options to add biological interpretation to our understanding of GWAS loci include colocalization
61 (Giambartolomei et al., 2014, 2018; Gleason et al., 2020; He et al., 2013) or Mendelian randomization
62 methods (Hauberg et al., 2017; Pavlides et al., 2016; Smith and Ebrahim, 2003). Another suite of tools
63 include transcriptome-wide association studies (TWAS), which integrate GWAS with expression
64 quantitative trait loci (eQTL) analyses to prioritize gene-trait associations (GTAs) with applications of
65 mediation analysis (Gamazon et al., 2015; Gusev et al., 2016) or Mendelian randomization (Zhang et al.,
66 2020). TWAS involves three general steps. First, per-gene predictive models of gene expression are
67 trained in the eQTL dataset using genetic variants. Then, genetically-regulated expression (GR_{EX}) is
68 imputed in the GWAS cohort with individual-level genotypes. Lastly, statistical associations between
69 GR_{EX} and trait are estimated (Barbeira et al., 2018; Gamazon et al., 2015; Gusev et al., 2016). TWAS is
70 also viable with GWAS summary statistics by estimating the test statistic of the TWAS association using a
71 proper LD reference panel (Gusev et al., 2016). Generally, most TWAS methods predict expression using
72 SNPs local to the gene within 1 Megabase of the gene body (Barbeira et al., 2018; Gamazon et al., 2015;
73 Gusev et al., 2016; Hu et al., 2019; Nagpal et al., 2019; Parrish et al., 2022; Zhou et al., 2020). Recently,
74 methods that include strong distal-eQTL signals have shown improved prediction and power to detect
75 GTAs (Bhattacharya et al., 2021a; Luningham et al., 2020). Nonetheless, practical and statistical
76 considerations to accurately prioritize GTAs through TWAS still require methodological improvement.

77

78 Along with those from traditional GWAS, TWAS introduces new challenges by incorporating gene
79 expression (Wainberg et al., 2019) (**Figure 1A**). On the genetic level, as in GWAS, disentangling signals
80 from complex LD structure, relatedness, and ancestry requires careful modeling considerations
81 (Mbatchou et al., 2020; Zhou et al., 2018). Selection of LD reference is specifically important in multi-
82 ancestry settings, like the GBMI, as LD structure across ancestry groups differs greatly (Shifman et al.,
83 2003). Mismatched LD may lead to gene expression models with reduced predictive power, reduced
84 power to detect GTAs, and increased false positives (Bhattacharya et al., 2020; Geoffroy et al., 2020;
85 Keys et al., 2020). In addition, phenotype acquisition and aggregation are challenging, especially across

86 multiple biobanks with different healthcare, electronic health record, and case-control definitions.
87 However, compared to GWAS, a challenge specific to TWAS is the integration of gene expression with
88 GWAS signal. Not only is it an active topic of methodological research to choose an optimal set of genes
89 and tissues that best explains the phenotype association at a given genetic locus, the role of context-
90 specific expression is still being evaluated in trait associations. Dynamic differences in bulk tissue
91 expression from cell-type- or cell-state-specificity can give additional granularity to gene-trait associations.
92 The impact of these challenges in a meta-analytic framework has not been previously explored.
93
94 Here, we outline a framework for analyzing trans-ancestry, meta-analytic GWAS across multiple biobanks
95 with TWAS. We review and explore practical considerations for all three steps (**Figure 1B**): ancestry
96 specificity of expression models and LD reference panels, meta-analytic techniques for detection of
97 GTAs, and follow-up tests and analyses for biological context. Our framework can be applied to various
98 phenotypes to study population-wide and ancestry-specific genetic associations mediated by tissue-
99 specific expression.

100

101 **RESULTS**

102 ***Expression models are not portable across ancestry groups***

103 The diversity represented in the GBMI enables uniquely well-powered studies to detect genetic
104 associations in non-European populations. However, optimal TWAS requires ancestry-matched training
105 datasets of genetic and tissue-specific gene expression data, which are still lacking in non-European
106 samples. As Cao *et al* points out (Cao et al., 2021), statistical power to detect GTAs in TWAS is
107 dependent on expression heritability and the ability of the predictive expression model to recapitulate that
108 heritable expression in the external GWAS panel. Accordingly, training expression models that perform
109 well in all ancestry populations is necessary to ensure that discoveries made through TWAS are not
110 restricted to European populations. For the first GBMI TWAS, we restrict analysis to populations of
111 European ancestry, due to small sample sizes of non-European ancestry samples (Aguet et al., 2020).
112 However, as sample sizes for eQTL datasets in non-European populations increase, the TWAS pipeline

113 will include expression models for these understudied and underserved populations (**STAR Methods**).

114 Here, we illustrate some challenges in building these expression models across ancestry groups.

115

116 We considered the 5 tissues in GTEx with at least 70 samples from both European (EUR) and African
117 (AFR) ancestry: subcutaneous adipose (abbreviated ADIP, $N = 71$ samples of AFR ancestry and 492
118 samples of EUR ancestry), tibial artery (ARTERY, $N = 76$ and 489), skeletal muscle (MUSC, $N = 86$ and
119 602), sun exposed lower leg skin (SKIN, $N = 73$ and 518), and whole blood (BLOOD, $N = 80$ and 574).

120 For genes with significantly heritable expression in both EUR and AFR GTEx samples (restricted
121 maximum likelihood-based estimate of heritability > 0 with nominal $P < 0.01$), we trained EUR- and AFR-
122 specific models using elastic net regularized regression (Friedman et al., 2010) and imputed expression
123 into the aligned (i.e., training and imputation samples have similar ancestries) and misaligned (i.e.,
124 training and imputation sample have different ancestries). For context, we also built ancestry-unaware
125 models, where EUR and AFR samples were pooled together. We calculated predictive performance with
126 adjusted R^2 to account for sample size, using leave-one-out CV when measuring predicting performance
127 in an aligned imputation sample (**STAR Methods**).

128

129 Across these tissues, models trained in EUR samples performed, on average, 4 times worse (differences
130 of 0.03-0.04 in median adjusted R^2) in AFR samples compared to models trained in AFR samples (**Figure**
131 **2A, Tables S1-S3**), with more than 80% of gene models with stronger performance if trained in AFR
132 samples. Similar trends hold for ancestry-specific models imputed into down-sampled EUR imputation
133 samples (**Figure S1-S2, Table S1-S3**), consistent with previous simulation and real-world studies
134 (Bhattacharya et al., 2020; Keys et al., 2020); here, we considered a randomly selected EUR imputation
135 sample with equal sample size to that of the AFR sample in the same tissue. In fact, we observed that
136 ancestry-specific models imputed into a sample with aligned ancestry showed larger predictive R^2 than
137 ancestry-unaware (individuals of EUR and AFR ancestry in the training sample) models imputed into the
138 same sample (**Figure 2B, Table S4**), despite generally increased sample sizes. This observation also
139 holds if we further increase the sample size of the training sample by including individuals of other
140 ancestries (Asian, American Indian, and Unknown ancestries) into the training sample (**Figure S3**). This

141 observation emphasizes the need for ancestry matching in gene prediction from genetic data and greater
142 recruitment of non-European ancestry patients in eQTL studies.

143

144 In these analyses, one reason ancestry-unaware models may perform poorly in AFR samples is due to
145 differences in minor allele frequency (MAF) of highly predictive SNPs between EUR and AFR ancestry
146 populations. It is important to note that this discrepancy is not generally specific to any one ancestry;
147 rather, ancestry imbalance in the training or reference datasets may lead to poor portability of genetic
148 models due to differences in allele frequency. To account for common SNPs in both AFR or EUR
149 ancestry populations, we additionally trained ancestry-unaware and ancestry-specific models using SNPs
150 with minor allele frequency (MAF) exceeding various thresholds in both AFR and EUR samples.
151 Excluding SNPs with $MAF < 0.01$ improved predictive performance of ancestry-unaware models across
152 all tissues (**Figure S4, Table S5**). However, the gap in predictive performance between ancestry-specific
153 and ancestry-unaware models did not decrease when the MAF cutoff was increased (**Figure 2B, Table**
154 **S4**). This observation may reflect that dropping ancestry-specific rarer SNPs ignores variants with large
155 ancestry-specific effects on gene expression. Additionally, excluding rare ancestry-specific SNPs does
156 not address the differences in LD across the EUR and AFR samples which leads to different
157 regularization paths and, hence, SNP-gene weights. Addressing the trans-ancestry portability of
158 expression models remains an open study direction; methodology that borrows information from
159 functional annotations or across different cell-type- or cell-state-specific contexts may bridge this gap in
160 predictive performance, similar to recent developments in polygenic risk score prediction for complex
161 traits (Amariuta et al., 2020; Márquez-Luna et al., 2020).

162

163 ***Meta-analytic strategies must be ancestry-aware***

164 Another critical consideration for the GBMI involves meta-analysis while using GWAS summary statistics.
165 TWAS estimates the association between GReX and the phenotype by weighting the standardized SNP-
166 trait effect sizes from GWAS summary statistics by SNP-gene weights from the expression models. To
167 account for the correlation between SNPs, an external LD reference panel, like the 1000Genomes Project
168 (Auton et al., 2015), is used to estimate the standard error of the TWAS association. Accordingly, the

169 accuracy of this reference panel to the LD structure in the GWAS cohort dictates how aligned the
170 summary-statistics based TWAS association is to the TWAS association from direct imputation into
171 individual-level genotypes in the GWAS cohort. Ideally, in-sample LD will give the best estimate of the
172 TWAS standard error, but several biobanks do not provide this information under their specific genetic
173 data sharing and privacy policies. Even departures in LD across subgroups of European ancestry
174 populations may influence the standard error estimate. In addition, as the estimates of SNP-gene weights
175 are influenced by the LD in the eQTL panel, differences in LD between the eQTL and GWAS panel will
176 also affect the TWAS effect size.

177

178 As LD structure greatly differs across ancestry groups (Shifman et al., 2003), pooling ancestry groups in
179 TWAS may lead to reduced power. We conducted TWAS for asthma risk using ancestry-unaware and
180 EUR- and AFR-specific models of whole blood expression (4,782 genes with heritable expression at
181 nominal $P < 0.01$ and models with cross-validation $R^2 > 0.01$ with nominal $P < 0.05$, trained via elastic net
182 regression). Ancestry-specific TWAS Z-scores across EUR and AFR ancestry groups were not strongly
183 correlated ($r = 0.11$), potentially due to differences in sample size and eQTL and GWAS architecture
184 (**Figure 3A, Figure S5-S6**) (Shang et al., 2020; Wyss et al., 2018). In fact, we detected only two genes
185 across both EUR and AFR with $P < 2.5 \times 10^{-6}$. One of these genes, *DFFA*, has been implicated with
186 asthma risk through GWAS and colocalization in EUR (Vicente et al., 2017). However, the TWAS
187 associations across EUR and AFR were in opposite directions using blood tissue. In the other 4 tissues
188 explored, *DFFA* TWAS associations did not reach transcriptome-wide significance but effect directions
189 were generally concordant (**Figure S7**). In blood, lead local-eQTLs (within 1 Megabase) of *DFFA* show
190 are in opposite directions, though only nominally significant at $P < 0.05$ (**Figure S8**). Although they are
191 within 60 kilobases, the lead eQTLs for *DFFA* across AFR (rs263526) and EUR (rs903916) are not in LD
192 ($R^2 = 3 \times 10^{-4}$ in AFR, 0.0072 in EUR). The GWAS effect sizes of SNPs local to *DFFA* do not show large
193 deviations in effect direction and are only nominally significant, as well (**Figure S8**). These differences in
194 TWAS associations across ancestry motivate careful consideration of meta-analytic strategy to avoid
195 biasing cross-ancestry associations towards cohorts with larger sample sizes, which still tend to be
196 predominantly of EUR ancestry.

197
198 We investigated 5 different meta-analytic strategies empirically: meta-analyzing across ancestry-specific,
199 per-biobank GWAS summary statistics using (1) inverse-variance weighting (IVW) and (2) sample-size
200 weighting (SSW), meta-analyzing across ancestry-specific meta-analyzed GWAS summary statistics
201 using (3) IVW and (4) SSW, and (5) TWAS using ancestry-unaware models and meta-analyzed GWAS
202 summary statistics across EUR and AFR ancestry groups (**STAR Methods**). QQ-plots in **Figure 3B** show
203 earlier departure of Z-scores from the QQ-line for SSW meta-analyzed Z-scores and the ancestry-
204 unaware strategy, suggesting inflation. This observation is supported with estimates of test statistic bias
205 and inflation using an empirical Bayes method, *bacon* (van Iterson et al., 2017), which show the largest
206 estimated bias and inflation for these SSW and ancestry-unaware methods. IVW strategies show similar
207 levels of inflation, with IVW meta-analysis across ancestry-specific meta-analyzed GWAS summary
208 statistics showing minimal bias (**Figure S9**). These results align with intuition – that the more naïve SSW
209 meta-analysis and ancestry-unaware methods bias towards EUR cohorts, which have the larger sample
210 sizes, whereas Z-scores from the IVW methods showed positive correlations with Z-scores from AFR
211 cohorts (**Figure S6**).

212
213 However, it is unclear whether ancestry-specific IVW meta-analysis to the per-biobank level is necessary.
214 As shown in **Figure S10**, Z-scores from these two IVW methods are moderately positively correlated ($r =$
215 0.51 across 4,152 Z-scores), with this correlation increasing when we consider genes with nominally
216 significant Z-scores for both strategies ($r = 0.70$ across 564 tests). We observed that top associations
217 across these IVW meta-analyses often had high degrees of heterogeneity in effect size across biobanks,
218 as measured by the Higgins-Thompson I^2 statistic (**Figure 3C, Figure S11**) (Higgins and Thompson,
219 2002). One gene, *A1BG*, that showed directionally concordant transcriptome-wide significant associations
220 across both IVW strategies had a large degree of heterogeneity in the underlying participating cohorts (I^2
221 $= 0.77$). In fact, the cross-biobank heterogeneity is often larger than the cross-ancestry heterogeneity for
222 TWAS associations of *A1BG*. Interestingly, *ZNF665*, another gene with directionally concordant
223 associations across both IVW strategies showed a low degree of heterogeneity in the per-biobank effect
224 sizes ($I^2 = 0.26$). However, genes with discordant associations across IVW strategies showed varied

225 patterns. Two illustrative examples are *MLNR* and *MYOZ3*, both with large degrees of test statistic
226 heterogeneity ($I^2 = 0.91$ and 0.82 , respectively). Across the two IVW strategies, effect sizes are in
227 opposite directions, possibly due to large standard error differences across the ancestry-specific per-
228 biobank associations. A thorough investigation of the power and false discovery rates of these meta-
229 analysis strategies through simulations is necessary. More sophisticated methods (Hedges and Vevea,
230 1998; Lee et al., 2017; Shi and Lee, 2016) that can properly incorporate the per-biobank uncertainty into
231 meta-analyzed TWAS associations must be explored to increase power and properly leverage the large
232 sample sizes of the GBMI.

233

234 In addition to considerations for TWAS in trans-ethnic populations, analyzing genetic data from individuals
235 of admixed ancestry is also an open area of study. For example, in this analysis, we have used the
236 1000Genomes AFR LD reference panel as an estimate of the LD for the AFR-ancestry samples from
237 each biobank. However, most of these AFR-ancestry populations are of admixed ancestry (e.g, African
238 Americans or African British). A single LD reference panel of AFR-ancestry may not reflect the genetic
239 diversity in these admixed populations of AFR and EUR ancestries from around the world (Baharian et
240 al., 2016). As Zhong et al highlights, in multiethnic and admixed populations, using local ancestry
241 estimates aids in better characterization of heritability of complex traits and more accurate mapping of
242 genetic associations, especially eQTLs (Zhong et al., 2019). Accordingly, incorporating local ancestry
243 estimates into both expression model step and the association testing step of TWAS may lead to
244 increased power and should be explored.

245

246 ***Follow-up tests provide biological and clinical context to TWAS GTAs***

247 TWAS GTAs identified using GWAS summary statistics are subject to several factors that may lead to
248 false positives. We implement several follow-up tests to provide context to TWAS-identified GTAs. First, a
249 TWAS GTA could attain transcriptome-wide significance due to only the strong SNP-trait associations
250 from the underlying GWAS. To quantify the significance of the GTA conditional on the SNP-trait effects at
251 the locus, we perform a permutation test by permuting the SNP-gene weights from the expression model
252 to generate a null distribution (**STAR Methods**). Comparing the original TWAS Z-score to this null

253 distribution assesses how much signal is added by the expression given the specific GWAS architecture
254 of the locus. As Gusev *et al* point out, this permutation test is highly conservative and intended to
255 prioritize only associations already significant in the standard TWAS GTA detection (Gusev et al., 2016).

256

257 Next, gene expression models for genes in adjacent genomic windows may be built from overlapping
258 SNPs or SNPs in strong LD. When TWAS detects GTAs in overlapping genomic regions, we apply
259 Bayesian probabilistic fine-mapping using FOCUS (Mancuso et al., 2019) to estimate a 90% credible set
260 of genes to explain the observed association signal in a given tissue (**STAR Methods**). However, the
261 current iteration of FOCUS has limitations. Priors for the correlation matrix between GReX of overlapping
262 genes are dependent on SNP LD reference panels. Thus, fine-mapping in trans-ancestry settings is
263 difficult, though recent machinery has been added to FOCUS to account for differences in genetic
264 architecture across the study sample (Gopalan and Lu et al, in preparation). Another challenge for gene-
265 level fine-mapping in multi-tissue TWAS is distinguishing between overlapping signals across tissues.
266 Primarily due to cross-cell-type variation in expression levels and eQTL architecture, TWAS may prioritize
267 genes in multiple tissues that are overrepresented by the same underlying causal cell-types (Wainberg et
268 al., 2019). This multi-tissue gene prioritization extends to fine-mapping overlapping TWAS signals across
269 tissue, as priors for FOCUS are not tissue-dependent. An interesting future direction involves careful
270 tissue-specific prior elicitation in TWAS fine-mapping – extracting posterior signal that is biologically
271 consistent and meaningful without allowing the prior to dominate.

272

273 The GBMI TWAS model incorporates gene expression models using MOSTWAS, a TWAS extension that
274 prioritizes distal-eQTLs by testing their mediation effect through local molecular features (**STAR**
275 **Methods**). For genes with models trained with MOSTWAS and associated with the trait at transcriptome-
276 wide significance, we test the additional association signal from the distal-SNPs using an added-last test,
277 analogous to a group-added-last test in linear regression (Bhattacharya et al., 2021a). This test also
278 prioritizes sets of genomic or epigenomic features that mediate the predicted distal-eQTLs for subsequent
279 study of upstream, tissue-specific regulation of GTAs. In one application of MOSTWAS, one prioritized
280 functional hypothesis was experimentally validated *in vitro* (Bhattacharya et al., 2021b). As distal-eQTLs

281 are more likely to be tissue- or cell-type-specific (Yang et al., 2017), the association signal from these
282 distal-eQTLs could also be leveraged in cross-tissue fine-mapping strategies.

283

284 Lastly, TWAS suffers from severely reduced power and inflated false positives in the presence of SNP
285 pleiotropy, where the genetic variants in the gene expression model affect the trait, independent of gene
286 expression (Veturi and Ritchie, 2018). We encourage estimating the degree of and accounting for SNP
287 pleiotropy using LDA-MR-Egger (Barfield et al., 2018) or PMR-Egger (Yuan et al., 2020), especially in
288 settings with individual-level GWAS genotypes. Applications for these methods using GWAS summary
289 statistics reveals some inflation of standard errors (Zhu et al., 2021), suggesting the need for further
290 evaluation and development of summary statistics-based methods to account for SNP pleiotropy in
291 TWAS GTA detection.

292

293 ***Biobanks enable GReX-PheWAS for biological context***

294 Biobanks aggregated in the GBMI provide a rich catalog of phenotypes for analysis, with phenotype
295 codes (phecodes) aggregated from ICD codes classified into clinically relevant categories (Wei et al.,
296 2017). This phenotype catalog enables Phenome-Wide Association Studies (PheWAS) as a complement
297 to GWAS by both replicating GWAS associations and providing a larger set of traits associations with
298 GWAS variants. To follow-up on novel TWAS-prioritized genes, we may expand the PheWAS framework
299 to the tissue-specific GReX level in a similarly complementary analysis: GReX-level Phenome-Wide
300 Association Study (GReX-PheWAS), as previously deployed in biobank settings and similar to the
301 PredixVU database (Pathak et al., 2020; Unlu et al., 2019, 2020). Not only do these analyses replicate
302 and detect new TWAS associations, but they can also point to groups of phenotypes that show
303 enrichments for trait-associations for the gene of interest.

304

305 We briefly illustrate an example of GReX-PheWAS using 3 genes (**Figure 4, Figure S12-S13, Table S6**):
306 *TAF7*, a novel gene in our TWAS, and *ILRAP18* and *TMEM258*, two genes previously implicated through
307 GWAS (Johansson et al., 2019; Portelli et al., 2020; Reijmerink et al., 2008, 2010; Zhu et al., 2020).

308 These genes were prioritized from European-specific TWAS for asthma risk from Zhou *et al* (Zhou et al.,

309 2021) using lung tissue expression (101,311 cases and 1,118,682 controls): *TAF7* (MOSTWAS model),
310 *IL18RAP* (JTI model), and *TMEM258* (JTI model). European-specific TWAS meta-analysis for asthma
311 detected a negative association with *TAF7* cis-GReX, a gene that did not intersect a GWAS-significant
312 locus. In TWAS follow-up tests, *TAF7* passed permutation testing and was estimated in the 90% credible
313 set at the genomic locus via FOCUS with posterior inclusion probability 1. *TAF7* encodes a component of
314 the TFIID protein complex, which binds to the TATA box in class II promoters and recruits RNA
315 polymerase II and other factors (Bhattacharya et al., 2014). As the clinically-relevant associations for
316 *TAF7* lung GReX are not characterized, we employed GReX-PheWAS in UKBB European-ancestry
317 GWAS summary statistics across 731 traits and diseases with sample sizes greater than 100,000,
318 grouped into 9 categories (**Figure 4, STAR Methods**). We see enrichments for phenotypes of the
319 hematopoietic and musculoskeletal groups (**Figure 4A**) with hypothyroidism and chronic laryngitis as the
320 top phenotype associations (**Figure 4B, Table S6**). These phenotypes include multiple inflammations of
321 organs (e.g., laryngitis, osteitis, meningitis, inflammations of the digestive and respiratory system, etc).
322 We also detected several associations with related respiratory diseases and traits. Similarly, for the two
323 previously implicated genes, we find enrichments for respiratory and hematopoietic GTAs for *ILRAP18*
324 and across multiple categories for *TMEM258*, consistent with the categorized functions and associations
325 of these genes (**Figure S12-S13, Table S6**). The utility of GBMI's robust roster of phenotypes enables
326 GReX-PheWAS to add biological and clinical context to novel TWAS associations.

327

328 GReX-PheWAS, despite its utility, shares the challenges of PheWAS. Phenotypes within and across
329 groups may be correlated, leading to a series of dependent tests. Even divergent phenotypes may be
330 correlated, either clinically or biologically. Thus, simple adjustments of multiple testing burden may not be
331 appropriate, and methods that account for correlation between phenotypes, like permutation tests, may
332 be more applicable (Hebbring, 2014; Korthauer et al., 2019; Stevens et al., 2017; Wei et al., 2017). In
333 addition, covariate adjustments in expression models built for disease-specific analyses may not be
334 generalizable for multiple phenotypes. Most population-based clinical biobanks lack comprehensive
335 clinical and lifestyle information of the individuals. Phenotyping information is typically incomplete, mostly
336 due to gaps in electronic health records. Phenotype groupings may also be deceptive: as most biobanks

337 follow ICD coding that groups traits and diseases by body systems, GReX-PheWAS enrichments for a
338 given group may not reflect shared genetic pathways across body systems. In addition, case-control
339 selection may not be optimal due to differences in exclusion criteria (McGuirl et al., 2020). Lastly,
340 phenotype acquisition and aggregation across multiple biobanks is challenging, with different healthcare,
341 electronic health record, and case-control definition assignments. Despite these limitations in phenotype
342 acquisition, recent methods focusing on identifying shared genetic architecture among multiple
343 phenotypes (McGuirl et al., 2020) in a phenome-wide approach highlight the advantages of GReX-
344 PheWAS.

345

346 **DISCUSSION**

347 Here, we provide a framework for TWAS in a multi-biobank setting across many ancestry groups. Our
348 work outlines several methodological gaps that should be addressed in the future: (1) training expression
349 models that are portable across ancestry groups, (2) limiting false discovery in TWAS by properly
350 modeling differences in LD across ancestry groups, (3) incorporating uncertainty within and heterogeneity
351 across biobanks to boost TWAS meta-analytic power, and (4) contextualizing TWAS GTAs through
352 follow-up testing, probabilistic fine-mapping across ancestry groups and expression contexts, and GReX-
353 PheWAS. Along with the discussed issues with current TWAS methodology, tissue-specific expression
354 may not provide sufficient granularity needed to discover trait-relevant biological mechanisms. Recent
355 methods that study the mediation of the SNP-trait relationship by cell-type heterogeneity show that cell-
356 types are influenced by genetics and predict complex traits (Liu et al., 2021). In turn, single-cell eQTL
357 datasets can be integrated with GWAS to identify cell-type- or cell-state-specific expression pathways that
358 are health- or disease-related. Incorporating single cell expression data into a predictive model will
359 require more sophisticated statistical methodology that relies on modeling cell identity as a spectrum,
360 rather than a categorical definition (Burkhardt et al., 2021; Verma and Engelhardt, 2020). Furthermore, a
361 multi-omic approach that incorporates functional data with TWAS may better model the flow of biological
362 information in a biologically interpretable fashion (Baca et al., 2021; Bhattacharya et al., 2021a), with
363 Zhao et al, in preparation.

364

365 Despite the limitations of this suite of methods, TWAS continues to be a useful tool for interpreting GWAS
366 associations and independently discovering genetic associations mediated by gene expression. There is
367 a severe need for an increase in reference eQTL data from individuals of non-European ancestry at parity
368 with those of European-ancestry individuals. Moreover, more sophisticated integrative computational and
369 experimental tools to complement improved TWAS and GWAS to understand the biology underlying
370 health and disease need to be developed.

371

372 **FUNDING**

373 BP was partially supported by NIH awards R01 HG009120, R01 MH115676, R01 CA251555, R01
374 AI153827, R01 HG006399, R01 CA244670, U01 HG011715. ERG is supported by the National Institutes
375 of Health (NIH) grants: NHGRI R35HG010718, NHGRI R01HG011138, NIA AG068026, and NIGMS
376 R01GM140287. NJC is supported by U01HG009086.

377

378 **DATA AND CODE AVAILABILITY**

379 The all-biobank and ancestry-specific GWAS summary statistics are publicly available for downloading at
380 <https://www.globalbiobankmeta.org/resources> and browsed at the PheWeb Browser
381 <http://results.globalbiobankmeta.org/>. 1000 Genome Phase 3 data can be accessed at
382 ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/data_collections/1000_genomes_project/data. MOSTWAS can
383 be accessed from <https://github.com/bhattacharya-a-bt/MOSTWAS>, and JTI can be accessed from
384 <https://github.com/gamazonlab/MR-JTI>. Sample scripts for this manuscript are available at
385 https://github.com/bhattacharya-a-bt/gbmi_twas.

386

387 **ACKNOWLEDGEMENTS**

388 We thank Nicholas Mancuso, Michael Love, and Achal Patel for their thoughtful discussion during the
389 research process. We would like to thank the organizing committee of the International Common Disease
390 Alliance for intellectual contributions on the set up of the GBMI as a nascent activity to the larger
391 effort. We would like to thank Daniel King from the Hail team and Sam Bryant from the Stanley Center
392 Data Management team at the Broad Institute for helping with the Google bucket set up and data

393 sharing, and Bethany Klunder from the University of Michigan Medical school for helping with the
394 paper submission.

395

396 **AUTHOR CONTRIBUTIONS**

397 Conceptualization: AB, JH; Methodology: AB, JH, DZ, ERG, BP, NJC; Software: AB, JH, DZ, ERG, BP,
398 NJC; Validation: AB, JH, DZ; Formal analysis: AB, JH; Investigation: all authors; Resources: all authors;
399 Data curation: WZ, MK; Writing - original draft: AB, JH; Writing - Review & Editing: all authors;
400 Visualization: AB, JH; Supervision: EG, BP, NJC; Project administration: AB, JH, ERG, BP, NJC; Funding
401 acquisition: all authors

402

403 **DECLARATION OF INTERESTS**

404 MJD is a founder of Maze Therapeutics. ERG receives an honorarium from the American Heart
405 Association, as a member of the Editorial Board of *Circulation Research*.

406

407 **FIGURE LEGENDS**

408 **Figure 1:** Overview of GBMI transcriptome-wide association study (TWAS) pipeline with challenges at
409 every data level. **(A)** Each level of data in TWAS introduces a unique set of challenges: (1) genetics data
410 include confounding from genetic ancestry, population structure and relatedness, and complex linkage
411 disequilibrium patterns, (2) gene expression data introduces context-specific factors, such as tissue-, cell-
412 type-, or cell-state-specific expression, and (3) phenotypic data, especially in the meta-analyses of
413 multiple biobanks, involve challenges in acquiring and aggregating phenotypes, properly defining controls
414 for phenotypes, and ascertainment and selection bias from non-random sampling. **(B)** An overview of the
415 GBMI TWAS pipeline: (1) JTI and MOSTWAS for model training, (2) inverse-variance weighted meta-
416 analysis using per-biobank, per-ancestry group TWAS summary statistics, and (3) various follow-up tests,
417 including conditional or permutation tests, distal-SNPs added last test, probabilistic fine-mapping using
418 FOCUS, and tests for SNP horizontal pleiotropy. Dotted lines represent associations that are tested in the
419 TWAS pipeline, while the solid lines represent a link built through predictive modeling.

420

421 **Figure 2: Comparison of predictive performance of genetic models of expression across ancestry. (A)**
422 Distribution of difference in adjusted R^2 (Y-axis) when predicting expression in the AFR imputation sample
423 between models trained in EUR and in AFR training samples across tissue (X-axis). **(B)** Distribution of
424 difference in adjusted R^2 between ancestry-specific and ancestry-unaware models imputing into EUR
425 (left) and AFR (right) samples.

426

427 **Figure 3: Comparison of meta-analytic strategies for multi-biobank, trans-ancestry TWAS. (A)** Scatterplot
428 of per-ancestry meta-analyzed TWAS scores across EUR (X-axis) and AFR ancestry (Y-axis). The dotted
429 horizontal and vertical lines indicate $P < 2.5 \times 10^{-6}$ with a diagonal line for reference. Points are colored
430 based on which ancestry population the TWAS association meets $P < 2.5 \times 10^{-6}$. **(B)** QQ-plot of TWAS
431 Z-scores, colored by meta-analytic strategies. Per ancestry refers to TWAS meta-analysis across meta-
432 analyzed ancestry-specific GWAS summary statistics. Per bank/per ancestry refers to TWAS meta-
433 analysis using all biobank- and ancestry-specific GWAS summary statistics. **(C)** Effect sizes and
434 Bonferroni-corrected confidence intervals (CIs) for TWAS associations across 17 individual biobanks
435 (stratified by ancestry group with EUR in green and AFR in red) and 2 IVW meta-analysis strategies (in
436 yellow) for 5 representative genes. The Higgins-Thompson I^2 statistic for heterogeneity is provided, with
437 the dotted line showing the null.

438

439 **Figure 4: GReX-PheWAS for categorizing phenome-wide associations for TAF7 genetically-regulated**
440 *expression in UKBB. (A)* Boxplots of $-\log_{10}$ Benjamini-Hochberg FDR-adjusted P-values of GTAs across 9
441 phenotype groups. The dotted grey line showed FDR-adjusted $P = 0.05$. **(B)** Miami plot of TWAS Z-
442 scores (Y-axis) across phenotypes, colored by phecode group. The dotted grey line shows the
443 significance threshold for Benjamini-Hochberg FDR correction and phenotypes are labelled if the
444 association passes Bonferroni correction.

445

446 **STAR METHODS**

447 We first outline the steps of the TWAS pipeline employed for phenotype available for analysis in the
448 GBMI. Then, we provide details for the analyses presented in **Results**.

449

450 ***The GBMI TWAS Pipeline***

451 *Training expression models from genetics*

452 Tissue-specific expression models trained with reference data from the Genotype-Tissue Expression
453 Project (GTEx) v8 (Aguet et al., 2020) are built using two methods: (1) Joint-Tissue Imputation (JTI),
454 which leverages shared genetic *cis*-regulation across tissues (Zhou et al., 2020), and (2) MOSTWAS,
455 which prioritizes tissue-specific distal-SNPs through rigorous mediation analysis to account for additional
456 expression heritability (Bhattacharya et al., 2021a). Genes with significantly positive expression
457 heritability (nominal $P < 0.05$) and five-fold cross-validation (CV) adjusted $R^2 \geq 0.01$ with $P < 0.05$ are
458 considered for TWAS. Ancestry-specific models are trained, excluding SNPs with MAF < 0.01 and
459 deviated from Hardy-Weinberg at $P < 10^{-5}$ across all 838 GTEx samples. The first iteration of the GBMI
460 TWAS pipeline focuses on EUR-ancestry models due to larger sample sizes. However, as sample sizes
461 for other ancestry groups increase, this pipeline can be adapted for these currently underrepresented
462 ancestries. In addition, models from other data sources using other methods can be incorporated in
463 subsequent steps.

464

465 *Hypothesis tests for TWAS*

466 To test for an association between tissue-specific GReX of a gene and a trait of interest, GWAS summary
467 statistics are integrated with these expression models. For the EUR-specific TWAS, we use EUR-specific
468 meta-analyzed GWAS summary statistics across all biobanks. JTI and MOSTWAS use two different
469 approaches to test for a GTA. For MR-JTI, the posterior predictive distribution of GReX is estimated, and
470 multiple-instrumental-variable causal inference is used to estimate the GTA, controlling for overall
471 heterogeneity (Zhou et al., 2020). For MOSTWAS, a weighted burden test is constructed, as in FUSION
472 (Bhattacharya et al., 2021a; Gusev et al., 2016; Pasaniuc et al., 2014). Both of these methods require a
473 LD reference panel; the GTEx LD matrix is used as a reference. Taken together, these methods provide
474 effect sizes, standard errors, Z-scores (effect sizes standardized by standard error), and P-values for
475 GTAs. A GTA is transcriptome-wide significant using a Bonferroni correction across all tests run. The
476 number of tests run is equal to the sum of the number of significant gene models across all tissues.

477

478 Follow-up tests and analyses are then run to provide context to the TWAS GTAs. A permutation test is
479 run by shuffling the SNP-gene weights 1,000 times and determining the TWAS Z-score at each
480 permutation, generating a null distribution. The original TWAS Z-score is compared to this null distribution
481 to generate a permutation P-value; Benjamini-Hochberg FDR correction is used to account for multiple
482 testing burden here. This test examines whether the SNP-gene relationship provides more information
483 than just the SNP-trait association. Next, for MOSTWAS, the distal-SNPs added-last test is run to
484 measure the association from distal-SNPs in the expression models, conditional on the association from
485 local-SNPs (Bhattacharya et al., 2021a). This test prioritizes sets of mediating molecular features for the
486 SNP-gene relationship with significant effects on the trait. Lastly, for genes whose models are built using
487 SNPs from overlapping genomic regions, probabilistic fine-mapping via FOCUS (default parameters and
488 priors) is employed to determine a 90% credible set of genes that explain the gene-level association
489 signal at the locus (Mancuso et al., 2019). FOCUS also outputs posterior inclusion probabilities for each
490 gene in the 90% credible set.

491

492 ***Analysis of ancestry-specific and -unaware models***

493 To show the utility of ancestry-specific models, we train EUR- and AFR-specific models using elastic net
494 regression for 5 tissues with more than 70 samples from AFR ancestry patients: subcutaneous adipose
495 ($N = 492$ EUR, $N = 71$ AFR), tibial artery ($N = 489$ EUR, $N = 76$ AFR), skeletal muscle ($N = 602$ EUR,
496 $N = 86$ AFR), sun exposed lower leg skin ($N = 518$ EUR, $N = 73$ AFR), and whole blood ($N = 574$ EUR,
497 $N = 80$ AFR). To balance sample sizes in the imputation sample, we down-sampled the EUR ancestry
498 imputation sample to match the AFR imputation sample. We consider only genes with positive expression
499 heritability in both EUR and AFR training samples (Yang et al., 2011). We also build ancestry-unaware
500 models, where genotypes for EUR and AFR samples are pooled together in the training sample. We
501 calculate predictive performance in aligned and misaligned imputation samples based on ancestry; the
502 aligned imputation sample is one with ancestry that predominantly matches the ancestry of the training
503 sample. Predictive performance is measured with adjusted R^2 to account for sample size, using an
504 appropriate linear model between predicted and observed expression. For imputation samples that are

505 used in training (aligned imputation panel), we use leave-one-out CV when measuring predictive
506 performance. Lastly, when imputing into AFR and EUR samples using the ancestry-unaware models, we
507 use leave-one-out CV, as well, but only cross-validating over the AFR or EUR samples, respectively.

508

509 **Comparison of meta-analytic strategies**

510 We compared 5 different meta-analytic strategies empirically: meta-analyzing across ancestry-specific,
511 per-biobank GWAS summary statistics using (1) inverse-variance weighting (IVW) and (2) sample-size
512 weighting (SSW), meta-analyzing across ancestry-specific meta-analyzed GWAS summary statistics
513 using (3) IVW and (4) SSW, and (5) TWAS using ancestry-unaware models into meta-analyzed GWAS
514 summary statistics across EUR and AFR ancestry groups. First, we consider three different sets of
515 GWAS summary statistics: biobank- and ancestry-specific summary statistics, ancestry-specific summary
516 statistics meta-analyzed across all biobanks, and summary statistics meta-analyzed across biobanks and
517 ancestry groups. In two former settings, for biobank i and a given gene, we generate $\beta_{TWAS,i}$, the TWAS
518 effect size, and $SE_{TWAS,i}$, the corresponding standard error. Given B different biobanks, the IVW TWAS Z-
519 score, $Z_{TWAS,IVW}$, is calculated as:

520

$$521 \quad Z_{TWAS,IVW} = \frac{\left(\frac{\sum_{i=1}^B \beta_{TWAS,i} / SE_{TWAS,i}}{\sum_{i=1}^B SE_{TWAS,i}^{-1}} \right)}{\left(\sum_{i=1}^B SE_{TWAS,i} \right)^{1/2}}.$$

522

523 With $Z_{TWAS,i} = \beta_{TWAS,i} / SE_{TWAS,i}$ and N_i as the sample size of the i th biobank (or pooled sample size
524 across all ancestry-specific biobank summary statistics), the SSW TWAS Z-score, $Z_{TWAS,SSW}$, is calculated
525 as:

526

$$527 \quad Z_{TWAS,SSW} = \frac{\sum_{i=1}^B N_i Z_{TWAS,i}}{\left(\sum_{i=1}^B N_i^2 \right)^{1/2}}.$$

528

529 For the ancestry-unaware TWAS, we use ancestry-unaware elastic net regression models and integrate
530 with GWAS summary statistics meta-analyzed across all ancestry groups and biobanks.

531

532 **GRex-level phenome-wide association studies (GRex-PheWAS)**

533 Transcriptome-wide significant genes are further prioritized by performing GRex-PheWAS to categorize
534 associations across a broad spectrum of phenotypes. Using UKBB summary statistics from European
535 ancestry patients (Bycroft et al., 2018), we tested for GTAs for 731 phenotypes grouped into 9 categories:
536 dermatologic, digestive, endocrine/metabolic, genitourinary, hematopoietic, musculoskeletal, neoplasms,
537 neurological, and respiratory. Here, we illustrate GRex-PheWAS using three genes from the European-
538 specific TWAS for asthma risk using lung tissue expression: *TAF7* (MOSTWAS model), *IL18RAP* (JTI
539 model), and *TMEM258* (JTI model). A phenome-wide significant association was defined via Bonferroni
540 correction ($P < \frac{0.05}{3 \times 731} = 2.28 \times 10^{-5}$).

541

542 **SUPPLEMENTAL INFORMATION**

543 **Table S1:** *Difference in adjusted R^2 between models trained in aligned and misaligned ancestry samples*
544 *as the ancestry of the imputation sample.*

545 **Table S2:** *R^2 of ancestry-specific models imputed into EUR imputation sample (training:imputation)*

546 **Table S3:** *R^2 of ancestry-specific models imputed into AFR imputation sample (training:imputation)*

547 **Table S4:** *Difference in R^2 between ancestry-specific and ancestry-unaware models across MAF*

548 **Table S5:** *Cross-validation R^2 of ancestry-unaware models across MAF threshold*

549 **Table S6:** *GRex-PheWAS results for 3 representative genes from asthma meta-analytic TWAS in*
550 *Europeans in GBMI that meet Bonferroni correction ($P < 0.05/731$)*

551 **Figure S1:** *Ratio of predictive performance of expression models in aligned versus misaligned imputation*
552 *samples across AFR (left) and EUR (right) ancestry in the imputation sample. Here, we down-sample the*
553 *EUR imputation sample to match the sample size of the AFR imputation sample.*

554 **Figure S2:** *Predictive performance of expression models in aligned and misaligned imputation samples.*

555 **Figure S3:** *Predictive performance of ancestry-unaware expression models compared to ancestry-*
556 *specific models across 5 tissues. Boxplot of difference in predictive performance in EUR (A) and AFR (B)*
557 *samples between ancestry-aligned models and ancestry-unaware models. We consider (1) individuals of*

558 all ancestry in the training sample of the ancestry-unaware model (gold) or only EUR and AFR individuals
559 in the training sample (grey). The red line indicates a difference of 0.

560 **Figure S4:** *Predictive performance of ancestry-unaware expression models across minor allele frequency*
561 *thresholds.*

562 **Figure S5:** *TWAS Miami plots across AFR and EUR ancestry groups for asthma using whole blood gene*
563 *expression models.*

564 **Figure S6:** *Correlation of TWAS Z-scores across ancestry-specific, individual biobank GWAS cohorts and*
565 *5 meta-analytic strategies.*

566 **Figure S7:** *TWAS associations across EUR and AFR ancestry groups for DFFA across 5 tissues.* The
567 effect size is given with the point (triangle if association is transcriptome-wide significant) with a 95%
568 confidence interval provided.

569 **Figure S8:** *Miami plots of DFFA local-eQTLs and GWAS signal for SNPs around DFFA.* In (A), color
570 shows linkage disequilibrium R^2 to lead eQTL SNP. Grey line shows a nominal P-value cutoff of 0.05 ($|Z|$
571 = 1.96).

572 **Figure S9:** *Empirical Bayes estimates of bias and inflation in TWAS Z-scores across meta-analysis*
573 *strategies.* Estimates of bias (top) and bottom (inflation) with one standard error width around the
574 estimate are given across meta-analysis strategies. The dotted lines provide a reference for the null (0 for
575 bias and 1 for inflation).

576 **Figure S10:** *Comparison of two IVW meta-analyzed Z-scores.* Vertical and horizontal dotted lines give a
577 reference for the Bonferroni-corrected threshold for transcriptome-significance. A diagonal line is provided
578 from reference.

579 **Figure S11:** *Comparison of meta-analyzed Z-scores with individual biobank TWAS Z-scores.* Ancestry-
580 specific TWAS Z-scores for individual biobanks are shown in the top panel, colored by ancestry. Meta-
581 analyzed Z-scores are shown in the bottom panel with shapes reflecting the different strategies. Dotted
582 lines provide a reference for transcriptome-wide significance.

583 **Figure S12:** *UKBB T-PheWAS associations across 5 representative asthma-associated genes through*
584 *European-only meta-analytic TWAS, grouped by phecode group.* The horizontal dotted line shows FDR-
585 adjusted $P = 0.05$.

586 **Figure S13:** *Miami plots of UKBB T-PheWAS associations across 2 genes previously implicated through*
587 *GWAS and detected in European-only meta-analytic TWAS in GBMI.*

588

589 REFERENCES

- 590 Abul-Husn, N.S., and Kenny, E.E. (2019). Personalized Medicine and the Power of Electronic Health
591 Records. *Cell* *177*, 58–69.
- 592 Aguet, F., Barbeira, A.N., Bonazzola, R., Brown, A., Castel, S.E., Jo, B., Kasela, S., Kim-Hellmuth, S., Liang,
593 Y., Oliva, M., et al. (2020). The GTEx Consortium atlas of genetic regulatory effects across human tissues.
594 *Science* *369*, 1318–1330.
- 595 Amariuta, T., Ishigaki, K., Sugishita, H., Ohta, T., Koido, M., Dey, K.K., Matsuda, K., Murakami, Y., Price,
596 A.L., Kawakami, E., et al. (2020). Improving the trans-ancestry portability of polygenic risk scores by
597 prioritizing variants in predicted cell-type-specific regulatory elements. *Nature Genetics* *52*, 1346–1354.
- 598 Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A., Clark, A.G.,
599 Donnelly, P., Eichler, E.E., Flicek, P., et al. (2015). A global reference for human genetic variation. *Nature*
600 *526*, 68–74.
- 601 Baca, S., Singler, C., Zacharia, S., Seo, J.-H., Morova, T., Hach, F., Ding, Y., Schwarz, T., Flora Huang, C.-C.,
602 Kalita, C., et al. (2021). Genetic determinants of chromatin reveal prostate cancer risk mediated by
603 context-dependent gene regulation. *BioRxiv* 2021.05.10.443466.
- 604 Baharian, S., Barakatt, M., Gignoux, C.R., Shringarpure, S., Errington, J., Blot, W.J., Bustamante, C.D.,
605 Kenny, E.E., Williams, S.M., Aldrich, M.C., et al. (2016). The Great Migration and African-American
606 Genomic Diversity. *PLoS Genetics* *12*, e1006059.
- 607 Barbeira, A.N., Dickinson, S.P., Bonazzola, R., Zheng, J., Wheeler, H.E., Torres, J.M., Torstenson, E.S.,
608 Shah, K.P., Garcia, T., Edwards, T.L., et al. (2018). Exploring the phenotypic consequences of tissue
609 specific gene expression variation inferred from GWAS summary statistics. *Nature Communications* *9*, 1–
610 20.
- 611 Barfield, R., Feng, H., Gusev, A., Wu, L., Zheng, W., Pasaniuc, B., and Kraft, P. (2018). Transcriptome-wide
612 association studies accounting for colocalization using Egger regression. *Genetic Epidemiology* *42*, 418–
613 433.
- 614 Bhattacharya, A., García-Closas, M., Olshan, A.F., Perou, C.M., Troester, M.A., and Love, M.I. (2020). A
615 framework for transcriptome-wide association studies in breast cancer in diverse study populations.
616 *Genome Biology* *21*, 42.
- 617 Bhattacharya, A., Li, Y., and Love, M.I. (2021a). MOSTWAS: Multi-Omic Strategies for Transcriptome-
618 Wide Association Studies. *17*, e1009398.
- 619 Bhattacharya, A., Freedman, A.N., Avula, V., Harris, R., Liu, W., Pan, C., Lusi, A.J., Joseph, R.M.,
620 Smeester, L., Hartwell, H.J., et al. (2021b). Genetic control of fetal placental genomics contributes to
621 development of health and disease. *MedRxiv* 2021.04.12.21255170.

- 622 Bhattacharya, S., Lou, X., Hwang, P., Rajashankar, K.R., Wang, X., Gustafsson, J.Å., Fletterick, R.J.,
623 Jacobson, R.H., and Webb, P. (2014). Structural and functional insight into TAF1-TAF7, a subcomplex of
624 transcription factor II D. *Proceedings of the National Academy of Sciences of the United States of*
625 *America* *111*, 9103–9108.
- 626 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau,
627 O., O’Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and genomic data.
628 *Nature* *562*, 203–209.
- 629 Cao, C., Ding, B., Li, Q., Kwok, D., Wu, J., and Long, Q. (2021). Power analysis of transcriptome-wide
630 association study: Implications for practical protocol choice. *PLoS Genetics* *17*, e1009405.
- 631 Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization Paths for Generalized Linear Models via
632 Coordinate Descent. *Journal of Statistical Software* *33*, 1–22.
- 633 Gallagher, M.D., and Chen-Plotkin, A.S. (2018). The Post-GWAS Era: From Association to Function.
634 *American Journal of Human Genetics* *102*, 717–730.
- 635 Gamazon, E.R., Wheeler, H.E., Shah, K.P., Mozaffari, S. v, Aquino-Michaels, K., Carroll, R.J., Eyler, A.E.,
636 Denny, J.C., Nicolae, D.L., Cox, N.J., et al. (2015). A gene-based association method for mapping traits
637 using reference transcriptome data. *Nature Genetics* *47*, 1091–1098.
- 638 Geoffroy, E., Gregga, I., and Wheeler, H.E. (2020). Population-Matched Transcriptome Prediction
639 Increases TWAS Discovery and Replication Rate. *IScience* *23*, 101850.
- 640 Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and Plagnol, V.
641 (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary
642 Statistics. *PLoS Genetics* *10*, e1004383.
- 643 Giambartolomei, C., Liu, J.Z., Zhang, W., Hauberg, M., Shi, H., Boocock, J., Pickrell, J., Jaffe, A.E.,
644 Pasaniuc, B., and Roussos, P. (2018). A Bayesian framework for multiple trait colocalization from
645 summary association statistics. *Bioinformatics* *34*, 2538–2545.
- 646 Gleason, K.J., Yang, F., Pierce, B.L., He, X., and Chen, L.S. (2020). Primo: Integration of multiple GWAS
647 and omics QTL summary statistics for elucidation of molecular mechanisms of trait-associated SNPs and
648 detection of pleiotropy in complex traits. *Genome Biology* *21*, 236.
- 649 Gusev, A., Ko, A., Shi, H., Bhatia, G., Chung, W., Penninx, B.W.J.H., Jansen, R., de Geus, E.J.C., Boomsma,
650 D.I., Wright, F.A., et al. (2016). Integrative approaches for large-scale transcriptome-wide association
651 studies. *Nature Genetics* *48*, 245–252.
- 652 Hauberg, M.E., Zhang, W., Giambartolomei, C., Franzén, O., Morris, D.L., Vyse, T.J., Ruusalepp, A.,
653 Fromer, M., Sieberts, S.K., Johnson, J.S., et al. (2017). Large-Scale Identification of Common Trait and
654 Disease Variants Affecting Gene Expression. *American Journal of Human Genetics* *100*, 885–894.
- 655 He, X., Fuller, C.K., Song, Y., Meng, Q., Zhang, B., Yang, X., and Li, H. (2013). Sherlock: Detecting gene-
656 disease associations by matching patterns of expression QTL and GWAS. *American Journal of Human*
657 *Genetics* *92*, 667–680.


- 658 Hebbring, S.J. (2014). The challenges, advantages and future of phenome-wide association studies.
659 *Immunology* *141*, 157–165.
- 660 Hedges, L., and Vevea, J. (1998). Fixed- and random-effects models in meta-analysis. *Psychological*
661 *Methods* *3*, 486–504.
- 662 Higgins, J.P.T., and Thompson, S.G. (2002). Quantifying heterogeneity in a meta-analysis. *Statistics in*
663 *Medicine* *21*, 1539–1558.
- 664 Hu, Y., Li, M., Lu, Q., Weng, H., Wang, J., Zekavat, S.M., Yu, Z., Li, B., Gu, J., Muchnik, S., et al. (2019). A
665 statistical framework for cross-tissue transcriptome-wide association analysis. *Nature Genetics* *51*, 568–
666 576.
- 667 van Iterson, M., van Zwet, E.W., Heijmans, B.T., and Heijmans, B.T. (2017). Controlling bias and inflation
668 in epigenome- and transcriptome-wide association studies using the empirical null distribution. *Genome*
669 *Biology* *18*, 19.
- 670 Johansson, Å., Rask-Andersen, M., Karlsson, T., and Ek, W.E. (2019). Genome-wide association analysis
671 of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema.
672 *Human Molecular Genetics* *28*, 4022–4041.
- 673 Keys, K.L., Mak, A.C.Y., White, M.J., Eckalbar, W.L., Dahl, A.W., Mefford, J., Mikhaylova, A. v., Contreras,
674 M.G., Elhawary, J.R., Eng, C., et al. (2020). On the cross-population generalizability of gene expression
675 prediction models. *PLoS Genetics* *16*, e1008927.
- 676 Korthauer, K., Kimes, P.K., Duvallet, C., Reyes, A., Subramanian, A., Teng, M., Shukla, C., Alm, E.J., and
677 Hicks, S.C. (2019). A practical guide to methods controlling false discoveries in computational biology.
678 *Genome Biology* *20*, 1–21.
- 679 Lee, C.H., Eskin, E., and Han, B. (2017). Increasing the power of meta-analysis of genome-wide
680 association studies to detect heterogeneous effects. In *Bioinformatics*, (Oxford University Press), pp.
681 i379–i388.
- 682 Luningham, J.M., Chen, J., Tang, S., de Jager, P.L., Bennett, D.A., Buchman, A.S., and Yang, J. (2020).
683 Bayesian Genome-wide TWAS Method to Leverage both cis- and trans-eQTL Information through
684 Summary Statistics. *American Journal of Human Genetics* *107*, 714–726.
- 685 Mancuso, N., Freund, M.K., Johnson, R., Shi, H., Kichaev, G., Gusev, A., and Pasaniuc, B. (2019).
686 Probabilistic fine-mapping of transcriptome-wide association studies. *Nature Genetics* *51*, 675–682.
- 687 Márquez-Luna, C., Gazal, S., Loh, P.R., Kim, S.S., Furlotte, N., Auton, A., and Price, A.L. (2020). LDpred-
688 funct: incorporating functional priors improves polygenic prediction accuracy in UK Biobank and
689 23andMe data sets. *BioRxiv*.
- 690 Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C.,
691 O’Dushlaine, C., Barber, M., Boutkov, B., et al. (2020). Computationally efficient whole genome
692 regression for quantitative and binary traits. *BioRxiv* 2020.06.19.162354.

- 693 McGuirl, M.R., Smith, S.P., Sandstede, B., and Ramachandran, S. (2020). Detecting shared genetic
694 architecture among multiple phenotypes by hierarchical clustering of gene-level association statistics.
695 *Genetics* 215, 511–529.
- 696 Nagpal, S., Meng, X., Epstein, M.P., Tsoi, L.C., Patrick, M., Gibson, G., de Jager, P.L., Bennett, D.A., Wingo,
697 A.P., Wingo, T.S., et al. (2019). TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation
698 Enhances Gene Mapping of Complex Traits. *American Journal of Human Genetics* 105, 258–266.
- 699 Parrish, R.L., Gibson, G.C., Epstein, M.P., and Yang, J. (2022). TIGAR-V2: Efficient TWAS tool with
700 nonparametric Bayesian eQTL weights of 49 tissue types from GTEx V8. *Human Genetics and Genomics
701 Advances* 3, 100068.
- 702 Pasaniuc, B., Zaitlen, N., Shi, H., Bhatia, G., Gusev, A., Pickrell, J., Hirschhorn, J., Strachan, D.P., Patterson,
703 N., Price, A.L., et al. (2014). Fast and accurate imputation of summary statistics enhances evidence of
704 functional enrichment. *Bioinformatics* 30, 2906–2914.
- 705 Pathak, G.A., Singh, K., Miller-Fleming, T.W., Wendt, F., Ehsan, N., Hou, K., Johnson, R., Lu, Z., Gopalan,
706 S., Dimbou, L.Y., et al. (2020). Integrative analyses identify susceptibility genes underlying COVID-19
707 hospitalization. *MedRxiv*.
- 708 Pavlides, J.M.W., Zhu, Z., Gratten, J., McRae, A.F., Wray, N.R., and Yang, J. (2016). Predicting gene
709 targets from integrative analyses of summary data from GWAS and eQTL studies for 28 human complex
710 traits. *Genome Medicine* 8, 84.
- 711 Portelli, M.A., Nicole Dijk, F., Ketelaar, M.E., Shrine, N., Hankinson, J., Bhaker, S., Grotenboer, N.S.,
712 Obeidat, M., Henry, A.P., Billington, C.K., et al. (2020). Phenotypic and functional translation of IL1RL1
713 locus polymorphisms in lung tissue and asthmatic airway epithelium. *JCI Insight* 5.
- 714 Reijmerink, N.E., Postma, D.S., Bruinenberg, M., Nolte, I.M., Meyers, D.A., Bleecker, E.R., and
715 Koppelman, G.H. (2008). Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with
716 asthma and atopy. *Journal of Allergy and Clinical Immunology* 122, 651-654.e8.
- 717 Reijmerink, N.E., Postma, D.S., and Koppelman, G.H. (2010). The candidate gene approach in asthma:
718 what happens with the neighbours? *European Journal of Human Genetics* 17.
- 719 Shang, L., Smith, J.A., Zhao, W., Kho, M., Turner, S.T., Mosley, T.H., Kardia, S.L.R., and Zhou, X. (2020).
720 Genetic Architecture of Gene Expression in European and African Americans: An eQTL Mapping Study in
721 GENOA. *American Journal of Human Genetics* 106, 496–512.
- 722 Shi, J., and Lee, S. (2016). A novel random effect model for GWAS meta-analysis and its application to
723 trans-ethnic meta-analysis. *Biometrics* 72, 945–954.
- 724 Shifman, S., Kuypers, J., Kokoris, M., Yakir, B., and Darvasi, A. (2003). Linkage disequilibrium patterns of
725 the human genome across populations. *Human Molecular Genetics* 12, 771–776.
- 726 Smith, G.D., and Ebrahim, S. (2003). ‘Mendelian randomization’: can genetic epidemiology contribute to
727 understanding environmental determinants of disease? *International Journal of Epidemiology* 32, 1–22.
- 728 Stevens, J.R., Masud, A. al, and Suyundikov, A. (2017). A comparison of multiple testing adjustment
729 methods with block-correlation positivelydependent tests. *PLoS ONE* 12.


- 730 Swede, H., Stone, C.L., and Norwood, A.R. (2007). National population-based biobanks for genetic
731 research. *Genetics in Medicine* 9, 141–149.
- 732 Unlu, G., Gamazon, E.R., Qi, X., Levic, D.S., Bastarache, L., Denny, J.C., Roden, D.M., Mayzus, I., Breyer,
733 M., Zhong, X., et al. (2019). GRIK5 Genetically Regulated Expression Associated with Eye and Vascular
734 Phenomes: Discovery through Iteration among Biobanks, Electronic Health Records, and Zebrafish. *The*
735 *American Journal of Human Genetics* 104, 503–519.
- 736 Unlu, G., Qi, X., Gamazon, E.R., Melville, D.B., Patel, N., Rushing, A.R., Hashem, M., Al-Faifi, A., Chen, R.,
737 Li, B., et al. (2020). Phenome-based approach identifies RIC1 -linked Mendelian syndrome through
738 zebrafish models, biobank associations and clinical studies. *Nature Medicine* 2020 26:1 26, 98–109.
- 739 Veturi, Y., and Ritchie, M.D. (2018). How powerful are summary-based methods for identifying
740 expression-trait associations under different genetic architectures? In *Pacific Symposium on*
741 *Biocomputing*, (World Scientific Publishing Co. Pte Ltd), pp. 228–239.
- 742 Vicente, C.T., Revez, J.A., and Ferreira, M.A.R. (2017). Lessons from ten years of genome-wide
743 association studies of asthma. *Clinical and Translational Immunology* 6, e165.
- 744 Wainberg, M., Sinnott-Armstrong, N., Mancuso, N., Barbeira, A.N., Knowles, D.A., Golan, D., Ermel, R.,
745 Ruusalepp, A., Quertermous, T., Hao, K., et al. (2019). Opportunities and challenges for transcriptome-
746 wide association studies. *Nature Genetics* 51, 592–599.
- 747 Wei, W.Q., Bastarache, L.A., Carroll, R.J., Marlo, J.E., Osterman, T.J., Gamazon, E.R., Cox, N.J., Roden,
748 D.M., and Denny, J.C. (2017). Evaluating phecodes, clinical classification software, and ICD-9-CM codes
749 for phenome-wide association studies in the electronic health record. *PLoS ONE* 12.
- 750 Wijmenga, C., and Zhernakova, A. (2018). The importance of cohort studies in the post-GWAS era.
751 *Nature Genetics* 50, 322–328.
- 752 Wyss, A.B., Sofer, T., Lee, M.K., Terzikhan, N., Nguyen, J.N., Lahousse, L., Latourelle, J.C., Smith, A.V.,
753 Bartz, T.M., Feitosa, M.F., et al. (2018). Multiethnic meta-analysis identifies ancestry-specific and cross-
754 ancestry loci for pulmonary function. *Nature Communications* 9, 1–15.
- 755 Yang, F., Wang, J., Pierce, B.L., and Chen, L.S. (2017). Identifying cis-mediators for trans-eQTLs across
756 many human tissues using genomic mediation analysis. *Genome Research* 27, 1859–1871.
- 757 Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: a tool for genome-wide complex trait
758 analysis. *American Journal of Human Genetics* 88, 76–82.
- 759 Yuan, Z., Zhu, H., Zeng, P., Yang, S., Sun, S., Yang, C., Liu, J., and Zhou, X. (2020). Testing and controlling
760 for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association
761 studies. *Nature Communications* 11, 1–14.
- 762 Zhang, Y., Quick, C., Yu, K., Barbeira, A., Luca, F., Pique-Regi, R., Kyung Im, H., and Wen, X. (2020).
763 PTWAS: Investigating tissue-relevant causal molecular mechanisms of complex traits using probabilistic
764 TWAS analysis. *Genome Biology* 21, 1–26.

- 765 Zhong, Y., Perera, M.A., and Gamazon, E.R. (2019). On Using Local Ancestry to Characterize the Genetic
766 Architecture of Human Traits: Genetic Regulation of Gene Expression in Multiethnic or Admixed
767 Populations. *American Journal of Human Genetics* *104*, 1097–1115.
- 768 Zhou, D., Jiang, Y., Zhong, X., Cox, N.J., Liu, C., and Gamazon, E.R. (2020). A unified framework for joint-
769 tissue transcriptome-wide association and Mendelian randomization analysis. *Nature Genetics* *52*,
770 1239–1246.
- 771 Zhou, W., Nielsen, J.B., Fritsche, L.G., Dey, R., Gabrielsen, M.E., Wolford, B.N., LeFaive, J., VandeHaar, P.,
772 Gagliano, S.A., Gifford, A., et al. (2018). Efficiently controlling for case-control imbalance and sample
773 relatedness in large-scale genetic association studies. *Nature Genetics* *50*, 1335–1341.
- 774 Zhou, W., Kanai, M., Wu, K.-H.H., Humaira, R., Tsuo, K., Hirbo, J.B., Wang, Y., Bhattacharya, A., Zhao, H.,
775 Namba, S., et al. (2021). Global Biobank Meta-analysis Initiative: powering genetic discovery across
776 human diseases. *MedRxiv* *27*, 2021.11.19.21266436.
- 777 Zhu, A., Matoba, N., Wilson, E.P., Tapia, A.L., Li, Y., Ibrahim, J.G., Stein, J.L., and Love, M.I. (2021).
778 MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of allelic
779 heterogeneity. *PLOS Genetics* *17*, e1009455.
- 780 Zhu, Z., Guo, Y., Shi, H., Liu, C.L., Panganiban, R.A., Chung, W., O'Connor, L.J., Himes, B.E., Gazal, S.,
781 Hasegawa, K., et al. (2020). Shared genetic and experimental links between obesity-related traits and
782 asthma subtypes in UK Biobank. *Journal of Allergy and Clinical Immunology* *145*, 537–549.
- 783

A. TRANSCRIPTOME-WIDE ASSOCIATION STUDY



B. GBMI TWAS PIPELINE



I. Train expression models from germline genetics

- Cis-SNP, multi-tissue method: **JTI** (Zhou et al 2020, *Nat Gen*)
- Distal-SNP-enriched method: **MOSTWAS** (Bhattacharya et al 2021, *PLOS Genet*)
- Align genetic ancestry of eQTL and GWAS panels

II. Test for gene-trait associations

- Meta-analyze across biobanks and ancestry groups using properly aligned LD references with inverse-variance weights

III. Conduct follow-up tests for prioritized genes

- Conditional/permutation tests
- **FOCUS** to estimate credible set of causal genes at a locus (Mancuso et al 2019, *Nat Gen*)
- Distal SNP test for potential mediators in **MOSTWAS**
- Estimate the degree of SNP horizontal pleiotropy

Figure 1: Overview of GBMI transcriptome-wide association study (TWAS) pipeline with challenges at every data level. (A) Each level of data in TWAS introduces a unique set of challenges: (1) genetics data include confounding from genetic ancestry, population structure and relatedness, and complex linkage disequilibrium patterns, (2) gene expression data introduces context-specific factors, such as tissue-, cell-type-, or cell-state-specific expression, and (3) phenotypic data, especially in the meta-analyses of multiple biobanks, involve challenges in acquiring and aggregating phenotypes, properly defining controls for phenotypes, and ascertainment and selection bias from non-random sampling. **(B)** An overview of the GBMI TWAS pipeline: (1) JTI and MOSTWAS for model training, (2) inverse-variance weighted meta-analysis using per-biobank, per-ancestry group TWAS summary statistics, and (3) various follow-up tests, including conditional or permutation tests, distal-SNPs added last test, probabilistic fine-mapping using FOCUS, and tests for SNP horizontal pleiotropy. Dotted lines represent associations that are tested in the TWAS pipeline, while the solid lines represent a link built through predictive modeling.




Figure 2: Comparison of predictive performance of genetic models of expression across ancestry. **(A)** Distribution of difference in adjusted R^2 (Y-axis) when predicting expression in the AFR imputation sample between models trained in EUR and in AFR training samples across tissue (X-axis). **(B)** Distribution of difference in adjusted R^2 between ancestry-specific and ancestry-unaware models imputing into EUR (left) and AFR (right) samples.




Figure 3: Comparison of meta-analytic strategies for multi-biobank, trans-ancestry TWAS. (A) Scatterplot of per-ancestry meta-analyzed TWAS scores across EUR (X-axis) and AFR ancestry (Y-axis). The dotted horizontal and vertical lines indicate $P < 2.5 \times 10^{-6}$ with a diagonal line for reference. Points are colored based on which ancestry population the TWAS association meets $P < 2.5 \times 10^{-6}$. **(B)** QQ-plot of TWAS Z-scores, colored by meta-analytic strategies. Per ancestry refers to TWAS meta-analysis across meta-analyzed ancestry-specific GWAS summary statistics. Per bank/per ancestry refers to TWAS meta-analysis using all biobank- and ancestry-specific GWAS summary statistics. **(C)** Effect sizes and Bonferroni-corrected confidence intervals (CIs) for TWAS associations across 17 individual biobanks (stratified by ancestry group with EUR in green and AFR in red) and 2 IVW meta-analysis strategies (in yellow) for 5 representative genes. The Higgins-Thompson I^2 statistic for heterogeneity is provided, with the dotted line showing the null.

